The global conjugate vaccine market size attained a value of USD 16 billion in 2022 driven by increasing scientific research and the rising demand for meningococcal vaccine. The market is anticipated to grow at a CAGR of 11% during the forecast period of 2023-2031 to attain a value of USD 40.9 billion by 2031.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The governments of various countries are introducing favourable schemes and programs to accelerate and promote conjugate vaccination in their countries. This is also propelling the market growth. For instance, the Indian government rolled out an anti-pneumonia vaccine as a part of its Universal Immunisation Program. Moreover, countries like the Democratic Republic of Congo, Pakistan, and Nigeria account for the highest death rate of people with pneumonia under the age of five years. Hence, various non-profit organisations are rolling out vaccination drives while raising awareness regarding preventable diseases in the regions. This is anticipated to fuel the market growth for conjugate vaccine.
Pneumonia is one of the dominant causes of child death worldwide. The rising demand to prevent pneumonia and acute respiratory infections is aiding the market growth. Various benefits associated with conjugate vaccines are also increasing their use. They can not only easily result in herd immunity but also have an excellent safety record. Moreover, they improve immunity and memory while providing long-lasting protection. This is increasing the demand for pneumococcal vaccines that aids in the prevention of pneumonia, especially in emerging economies. As pneumococcal conjugate vaccines are suitable for major age groups, their demand is increasing, which, in turn, is invigorating the market growth.
A conjugated vaccine is a vaccine that is composed of weak antigens and a protein carrier molecule. It enhances the immune system and improves antigen’s immunogenicity. It also reduces asymptomatic carriage of the bacteria. Moreover, the vaccine is effective for a long period of time without resulting in any major side effects.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The major types of conjugate vaccine are:
The market can be broadly categorised on the basis of its disease indication into:
Based on pathogen type, the market is divided into:
On the basis of patient, the market is segmented into:
The EMR report looks into the regional markets of conjugate vaccine like North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
According to the World Health Organisation (WHO), meningococcal meningitis, the bacterial form of meningitis, is prevalent in sub-Saharan Africa ranging from Senegal in the west to Ethiopia in the east. As it occurs in the region each year between December and June, various organisations and governments are rolling out vaccination drives in the region. This is increasing the use of meningococcal vaccine, hence augmenting the market growth. Moreover, the launch of various immunisation programs to generate awareness regarding the benefits of conjugate vaccines is providing further impetus to the market growth.
The exponential rise in population is expected to increase the demand for various vaccines, especially among children. The rising attempts of various non-profit organisations for approvals of conjugate vaccines are increasing its demand, hence augmenting the market growth. Increasing scientific research to develop more efficient vaccines is further invigorating the market growth. In addition, the surge of novel pathogens, which can potentially cause severe illnesses, are anticipated to propel the growth of the conjugate vaccine industry in the forecast period. Moreover, the rising demand for diphtheria, pertussis, and tetanus vaccines among children to prevent complications is also catalysing the market growth, therefore significantly contributing to the overall industry growth.
The report presents a detailed analysis of the following key players in the global conjugate vaccine market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
The comprehensive report looks into the macro and micro aspects of the industry. The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Type||
|Breakup by Indications||
|Breakup by Pathogen Type||
|Breakup by Patient Type||
|Breakup by End User||
|Breakup by Region||
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Conjugate Vaccines Market Overview
3.1 Global Conjugate Vaccines Market Historical Value (2016-2022)
3.2 Global Conjugate Vaccines Market Forecast Value (2023-2031)
4 Global Conjugate Vaccines Market Landscape
4.1 Global Conjugate Vaccines Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Conjugate Vaccines Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Indications
4.2.3 Analysis by Pathogen Type
5 Global Conjugate Vaccines Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Conjugate Vaccines Market Segmentation
6.1 Global Conjugate Vaccines Market by Type
6.1.1 Market Overview
6.1.2 Monovalent Conjugate Vaccines
6.1.3 Multivalent Conjugate Vaccines
6.2 Global Conjugate Vaccines Market by Indications
6.2.1 Market Overview
6.2.2 Pneumococcal Disease
6.2.4 Meningococcal Disease
6.2.5 Diphtheria Tetanus and Pertussis (DTP)
6.3 Global Conjugate Vaccines Market by Pathogen Type
6.3.1 Market Overview
6.3.2 Bacterial Conjugate Vaccine
6.3.3 Viral Conjugate Vaccine
6.3.4 Combination (Viral and Bacterial)
6.4 Global Conjugate Vaccines Market by Patient Type
6.4.1 Market Overview
6.5 Global Conjugate Vaccines Market by End User
6.5.1 Market Overview
6.5.4 Homecare Settings
6.6 Global Conjugate Vaccines Market by Region
6.6.1 Market Overview
6.6.2 North America
6.6.4 Asia Pacific
6.6.5 Latin America
6.6.6 Middle East and Africa
7 North America Conjugate Vaccines Market
7.1 Market Share by Country
7.2 United States of America
8 Europe Conjugate Vaccines Market
8.1 Market Share by Country
8.2 United Kingdom
9 Asia Pacific Conjugate Vaccines Market
9.1 Market Share by Country
10 Latin America Conjugate Vaccines Market
10.1 Market Share by Country
11 Middle East and Africa Conjugate Vaccines Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.5 South Africa
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Clinical Trials Analysis
14.1 Analysis by Trial Registration Year
14.2 Analysis by Trial Status
14.3 Analysis by Trial Phase
14.4 Analysis by Therapeutic Area
14.5 Analysis by Geography
15 Funding Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
18 Supplier Landscape
18.1 Merck & Co., Inc.
18.1.1 Financial Analysis
18.1.2 Product Portfolio
18.1.3 Demographic Reach and Achievements
18.1.4 Mergers and Acquisitions
18.2 Novartis AG
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Mergers and Acquisitions
18.3 Serum Institute of India Pvt. Ltd.
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Mergers and Acquisitions
18.4 Pfizer Inc.
18.4.1 Financial Analysis
18.4.2 Product Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Mergers and Acquisitions
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Mergers and Acquisitions
18.6 Bharat Biotech
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Mergers and Acquisitions
18.7 Biological E
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Mergers and Acquisitions
18.8 GlaxoSmithKline plc.
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Mergers and Acquisitions
18.9 Astellas Pharma Inc.
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Mergers and Acquisitions
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Mergers and Acquisitions
18.11 SutroVax Inc.
18.11.1 Financial Analysis
18.11.2 Product Portfolio
18.11.3 Demographic Reach and Achievements
18.11.4 Mergers and Acquisitions
18.12 CSL Limited
18.12.1 Financial Analysis
18.12.2 Product Portfolio
18.12.3 Demographic Reach and Achievements
18.12.4 Mergers and Acquisitions
18.13 Bavarian Nordic
18.13.1 Financial Analysis
18.13.2 Product Portfolio
18.13.3 Demographic Reach and Achievements
18.13.4 Mergers and Acquisitions
18.14 Emergent BioSolutions Inc.
18.14.1 Financial Analysis
18.14.2 Product Portfolio
18.14.3 Demographic Reach and Achievements
18.14.4 Mergers and Acquisitions
18.15 Valneva SE
18.15.1 Financial Analysis
18.15.2 Product Portfolio
18.15.3 Demographic Reach and Achievements
18.15.4 Mergers and Acquisitions
18.16 Moderna, Inc.
18.16.1 Financial Analysis
18.16.2 Product Portfolio
18.16.3 Demographic Reach and Achievements
18.16.4 Mergers and Acquisitions
18.17.1 Financial Analysis
18.17.2 Product Portfolio
18.17.3 Demographic Reach and Achievements
18.17.4 Mergers and Acquisitions
18.18 Johnson & Johnson Services, Inc.
18.18.1 Financial Analysis
18.18.2 Product Portfolio
18.18.3 Demographic Reach and Achievements
18.18.4 Mergers and Acquisitions
18.19 Themis Bioscience GmbH
18.19.1 Financial Analysis
18.19.2 Product Portfolio
18.19.3 Demographic Reach and Achievements
18.19.4 Mergers and Acquisitions
18.20 B. Braun Melsungen AG
18.20.1 Financial Analysis
18.20.2 Product Portfolio
18.20.3 Demographic Reach and Achievements
18.20.4 Mergers and Acquisitions
19 Global Conjugate Vaccines Market - Distribution Model (Additional Insight)
19.2 Potential Distributors
19.3 Key Parameters for Distribution Partner Assessment
20 Key Opinion Leaders (KOL) Insights (Additional Insight)
21 Company Competitiveness Analysis (Additional Insight)
21.1 Very Small Companies
21.2 Small Companies
21.3 Mid-Sized Companies
21.4 Large Companies
21.5 Very Large Companies
22 Payment Methods (Additional Insight)
22.1 Government Funded
22.2 Private Insurance
*Additional insights provided are customisable as per client requirements.
In 2022, the global market for conjugate vaccine reached a value of USD 16 billion.
The market is anticipated to grow at a CAGR of 11% during the forecast period of 2023-2031 to reach a value of USD 40.9 billion by 2031.
The industry is being driven by favourable government initiatives and the rising attempts to prevent pneumonia—related deaths.
The market is expected to be driven by the increasing scientific research and the rising demand for meningococcal vaccine.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The major types of conjugate vaccine in the industry are monovalent conjugate vaccine and multivalent conjugate vaccine.
The significant disease indications in the market are pneumococcal, influenza, diphtheria tetanus and pertussis (DTP), and meningococcal, among others.
The leading pathogen types of conjugate vaccine are bacterial conjugate vaccine, viral conjugate vaccine, and combined conjugate vaccine.
The dominant patients of conjugate vaccine are adults and paediatrics.
The major players in the industry are Serum Institute of India Pvt., Ltd., Groupe Sanofi, Pfizer Inc., Novartis AG, and Bharat Biotech Ltd., among others.
Single User License
Five User License
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.